Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYPTNASDAQ:NVMINYSE:OUST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYPTEyePoint Pharmaceuticals$8.94+8.4%$6.12$3.91▼$13.99$615.17M1.61818,331 shs910,330 shsNVMINova$217.00+0.2%$190.81$154.00▼$289.90$6.38B1.61234,963 shs178,994 shsOUSTOuster$14.59+6.0%$9.23$5.84▼$16.88$784.45M2.471.35 million shs2.63 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYPTEyePoint Pharmaceuticals+8.36%+23.99%+46.80%+25.39%-8.68%NVMINova+0.25%+2.19%+8.11%-3.99%-0.70%OUSTOuster+6.03%+18.81%+76.63%+80.57%+21.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYPTEyePoint Pharmaceuticals2.4627 of 5 stars3.53.00.00.03.31.70.0NVMINova3.3269 of 5 stars3.44.00.00.02.01.71.9OUSTOuster1.2397 of 5 stars1.64.00.00.02.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYPTEyePoint Pharmaceuticals 3.00Buy$25.38183.84% UpsideNVMINova 2.80Moderate Buy$277.0027.65% UpsideOUSTOuster 3.14Buy$14.10-3.38% DownsideCurrent Analyst Ratings BreakdownLatest EYPT, NVMI, and OUST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/16/2025EYPTEyePoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/9/2025NVMINovaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$290.00 ➝ $280.005/9/2025NVMINovaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$295.00 ➝ $280.005/9/2025OUSTOusterWestpark CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$13.685/8/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $27.004/16/2025NVMINovaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$310.00 ➝ $248.003/27/2025OUSTOusterUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$16.003/27/2025OUSTOusterOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$16.003/21/2025OUSTOusterCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $11.003/21/2025OUSTOusterRosenblatt SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYPTEyePoint Pharmaceuticals$56.04M10.98N/AN/A$5.66 per share1.58NVMINova$743.95M8.58$5.59 per share38.82$31.94 per share6.79OUSTOuster$117.79M6.66N/AN/A$4.15 per share3.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYPTEyePoint Pharmaceuticals-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)NVMINova$183.76M$6.6237.8026.922.5527.33%22.33%15.01%8/6/2025 (Estimated)OUSTOuster-$374.11M-$1.97N/AN/AN/A-106.50%-65.17%-37.02%8/12/2025 (Estimated)Latest EYPT, NVMI, and OUST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NVMINova$2.08$2.18+$0.10$2.03$210.10 million$213.36 million5/7/2025Q1 2025EYPTEyePoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYPTEyePoint PharmaceuticalsN/AN/AN/AN/AN/ANVMINovaN/AN/AN/AN/AN/AOUSTOusterN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYPTEyePoint PharmaceuticalsN/A5.505.45NVMINovaN/A2.321.92OUSTOusterN/A3.122.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYPTEyePoint Pharmaceuticals99.41%NVMINova82.99%OUSTOuster31.45%Insider OwnershipCompanyInsider OwnershipEYPTEyePoint Pharmaceuticals4.46%NVMINova1.00%OUSTOuster7.81%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYPTEyePoint Pharmaceuticals12068.81 million65.02 millionOptionableNVMINova1,18029.40 million28.76 millionOptionableOUSTOuster28053.77 million45.88 millionOptionableEYPT, NVMI, and OUST HeadlinesRecent News About These CompaniesBangladesh to hold elections in April 2026, in a first since Sheikh Hasina's ouster, confirms YunusJune 6 at 12:58 PM | msn.comBreakout Momentum Plays You May Not Know About (OUST)June 6 at 11:54 AM | marketbeat.comOuster (NYSE:OUST) Trading Up 8.6% - Should You Buy?June 6 at 11:34 AM | marketbeat.comBrokers Suggest Investing in Ouster (OUST): Read This Before Placing a BetJune 6 at 10:32 AM | zacks.comAmid ouster of dean filmed in secret recording, UNCA warns more could be comingJune 5 at 9:57 PM | msn.comBengaluru stampede: Dy. CM breaks down over deaths, HDK demands his ouster from CabinetJune 5 at 4:55 PM | thehindu.comFormer Trump Nasa nominee suggests ties to Elon Musk caused his ousterJune 5 at 6:08 AM | straitstimes.comGujarat HC defers interim relief to Turkish Celebi in Ahmedabad airport ousterJune 5 at 6:08 AM | cnbctv18.comKnicks stars party in NYC after playoff ouster — hours before Tom Thibodeau firingJune 5 at 6:08 AM | msn.comWith Market Basket CEO’s ouster, could a boycott shape up in Maine?June 5 at 6:08 AM | pressherald.comOuster, Inc. (NYSE:OUST) Receives Consensus Rating of "Buy" from BrokeragesJune 5 at 1:32 AM | marketbeat.comFormer Trump NASA Nominee Suggests Ties to Musk Caused His OusterJune 4 at 5:52 PM | msn.comSenator wants VP ouster dismissedJune 4 at 12:50 PM | bworldonline.comJeff Teague describes Tom Thibodeau coaching style with hilarious impression after stunning Knicks ousterJune 4 at 12:50 PM | nypost.comKindiki Meets Mbarire, Embu Leaders to Stem Party Squabbles After UDA Ouster Plot EmergedJune 4 at 7:49 AM | kenyans.co.keNuveen Asset Management LLC Has $1.50 Million Stock Position in Ouster, Inc. (NYSE:OUST)June 4 at 3:36 AM | marketbeat.comThere’s going to be a movie about OpenAI CEO Sam Altman’s ouster (and subsequent rehire).June 4 at 2:49 AM | theverge.comOuster won't dampen Lancers' victorious springJune 4 at 2:49 AM | eagletribune.comKnicks fire Tom Thibodeau after playoff ouster in stunning shakeupJune 4 at 2:49 AM | nypost.comKnicks Fire Head Coach Tom Thibodeau After Playoff OusterJune 4 at 2:49 AM | msn.comSix months after Assad’s ouster, Syria faces major security, economic challengesJune 3, 2025 | timesofisrael.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBreakout Momentum Plays You May Not Know AboutBy Nathan Reiff | June 6, 2025View Breakout Momentum Plays You May Not Know AboutEYPT, NVMI, and OUST Company DescriptionsEyePoint Pharmaceuticals NASDAQ:EYPT$8.94 +0.69 (+8.36%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$8.80 -0.14 (-1.52%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Nova NASDAQ:NVMI$217.00 +0.54 (+0.25%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$214.88 -2.12 (-0.97%) As of 06/6/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nova Ltd. designs, develops, produces, and sells process control systems used in the manufacture of semiconductors in Israel, Taiwan, the United States, China, Korea, and internationally. Its product portfolio includes a set of metrology platforms for dimensional, films, and materials and chemical metrology measurements for process control for various semiconductor manufacturing process steps, including lithography, etch, chemical mechanical planarization, deposition, electrochemical plating, and advanced packaging. The company serves various sectors of the integrated circuit manufacturing industry, including logic, foundries, and memory manufacturers, as well as process equipment manufacturers. Nova Ltd. was formerly known as Nova Measuring Instruments Ltd. and changed its name to Nova Ltd. in July 2021. Nova Ltd. was incorporated in 1993 and is headquartered in Rehovot, Israel.Ouster NYSE:OUST$14.59 +0.83 (+6.03%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$14.63 +0.04 (+0.27%) As of 06/6/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ouster, Inc. provides lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries in Americas, the Asia-Pacific, Europe, the Middle East, and Africa. Its products include high-resolution scanning and solid-state digital lidar sensors, analog lidar sensors, and software solutions. The company offers Ouster Sensor, a scanning sensor; and Digital Flash, a solid-state flash sensor. It also provides surround-view lidar sensors, which include Ouster Gemini, a perception platform for smart infrastructure deployments; and Blue City, a Gemini-powered solution for traffic operations, planning, and safety. The company is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
